机构：[1]Oncology, Shanghai East Hospital, Tongji University, School of Medicine, Shanghai, China[2]The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China[3]Laboratory of Cellular and Molecular Radiation Oncology, Radiation Oncology Institute of Enze Medical Health Academy, Department of Pulmonary Medicine, Affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, China台州恩泽医疗中心台州医院[4]Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China[5]Department of Medical Oncology, Changzhou Cancer Hospital, Changzhou, China[6]Wuhan University Zhongnan Hospital, Wuhan, China[7]AnhuiCancer Hospital, Hefei, China[8]The First People's Hospital of Kunming, Kunming, China[9]Fudan University Shanghai Cancer Center, Shanghai, China[10]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[11]Shulan (Hangzhou) Hospital, Hangzhou, China[12]The Second Hospital of Anhui Medical University, Hefei, China[13]Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China[14]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[15]Changzhou Cancer Hospital of Soochow University, Changzhou, China[16]The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[17]Biotheus Inc., Beijing, China[18]Biotheus Inc., Shanghai, China
第一作者机构：[1]Oncology, Shanghai East Hospital, Tongji University, School of Medicine, Shanghai, China[2]The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China[3]Laboratory of Cellular and Molecular Radiation Oncology, Radiation Oncology Institute of Enze Medical Health Academy, Department of Pulmonary Medicine, Affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, China[4]Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China[5]Department of Medical Oncology, Changzhou Cancer Hospital, Changzhou, China[6]Wuhan University Zhongnan Hospital, Wuhan, China[7]AnhuiCancer Hospital, Hefei, China[8]The First People's Hospital of Kunming, Kunming, China[9]Fudan University Shanghai Cancer Center, Shanghai, China[10]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China[11]Shulan (Hangzhou) Hospital, Hangzhou, China[12]The Second Hospital of Anhui Medical University, Hefei, China[13]Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China[14]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[15]Changzhou Cancer Hospital of Soochow University, Changzhou, China[16]The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China[17]Biotheus Inc., Beijing, China[18]Biotheus Inc., Shanghai, China
推荐引用方式(GB/T 7714)：
Guo Ye,Liu Baogang,Lv Dongqing,et al.Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-ss, in patients with advanced tumors[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Guo, Ye,Liu, Baogang,Lv, Dongqing,Cheng, Ying,Zhou, Tong...&Hu, Guoqiang.(2022).Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-ss, in patients with advanced tumors.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Guo, Ye,et al."Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-ss, in patients with advanced tumors".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学